Dare Bioscience, Inc. quarterly report, Q3 FY2018

Dare Bioscience, Inc. — Q3 2018 Form 10-Q

Reporting period: Quarter and nine months ended September 30, 2018. Dare is a clinical-stage biopharmaceutical company developing women’s reproductive-health products. It reported no revenue from its primary business to date.

Key financial results

MetricThree months ended Sep. 30, 2018Nine months ended Sep. 30, 2018
Revenue$0$0
Operating expenses$2.62 million$13.92 million
Operating loss$2.62 million$13.92 million
Net loss$2.57 million$13.82 million
Net loss per share, basic and diluted$0.23$1.32
Net cash used in operating activitiesNot stated for the quarter$7.56 million
  • At September 30, cash and cash equivalents were $9.54 million; working capital was approximately $9 million. Total liabilities were $1.21 million, comprising $1.20 million of current liabilities and $9,292 of deferred rent. The filing reports no outstanding convertible notes or other debt balance.
  • Accumulated deficit was $26.05 million. No meaningful profit margin is applicable because the company had no revenue and incurred operating losses.
  • Cash increased by $1.98 million over the nine months, reflecting $10.11 million of financing proceeds, offset by operating and investing cash use and foreign-exchange effects. Financing proceeds included the February public offering and at-the-market sales.

Changes versus prior comparable periods

  • Q3 operating expenses rose $1.29 million year over year to $2.62 million, mainly from higher development spending on Ovaprene and Sildenafil Cream, increased preclinical-program costs, and higher payroll. Q3 net loss increased from $1.63 million to $2.57 million. The absence of prior-year convertible-note interest expense partly offset the higher operating loss.
  • Nine-month operating expenses rose $11.88 million to $13.92 million. The largest item was a $5.19 million goodwill impairment recorded in Q1; research and development expense increased $4.44 million and general and administrative expense increased $1.91 million. Nine-month net loss rose from $2.37 million to $13.82 million.
  • Comparisons require caution: the 2017 results reflect the Cerulean/Private Dare transaction completed July 19, 2017, with the nine-month period including Private Dare’s operations before that date. The filing says this makes period-to-period comparisons difficult.
  • Cash was $9.54 million, up from $7.56 million at December 31, 2017. Common shares outstanding were 11,422,161 at September 30, versus 6,047,161 at year-end 2017, reflecting equity financing and other share activity.

Outlook, developments and risks

  • Management said existing cash was expected to fund planned operating expenses for at least 12 months from issuance of the financial statements, while also stating that additional capital would be needed to execute the operating plan. The company expected continuing losses for at least several years and was evaluating financing, grant, collaboration and strategic-alliance options.
  • Ovaprene’s postcoital-test clinical trial began in May 2018; data were expected in the second half of 2019. If results support further development, the company intended to prepare an FDA Investigational Device Exemption for a pivotal trial. The FDA had designated the device center as lead and indicated that a Premarket Approval pathway would be required.
  • Following an FDA Type C meeting, the company planned to begin Phase 2b-related activities for Sildenafil Cream, 3.6%, in Q4 2018, starting with a patient-reported-outcome content-validity study. Timing of the later at-home Phase 2b trial would depend in part on further FDA feedback.
  • The portfolio expanded through agreements and acquisitions in 2018, including the Pear Tree vaginal tamoxifen asset, Juniper’s intravaginal-ring rights, Orbis injectable contraceptive candidates and Hydra assets. These programs entail development spending and potential milestone, royalty or other payments. Pear Tree consideration may include contingent milestones and royalties.
  • Significant risks include clinical or regulatory failure or delay, inability to raise capital on acceptable terms, reliance on third parties, and potential dilution. The company disclosed that its public float was approximately $9.8 million and that Form S-3 primary offerings were subject to the one-third-of-public-float limit under applicable rules—approximately $3.3 million assuming the float remained unchanged.
  • The company recognized $213,000 of grant funding as a reduction of R&D expense in the quarter and nine-month period. The NIH award’s anticipated total was $1.9 million, but future funding was contingent on review of results and availability of funds.
  • No material pending legal proceedings were reported. Management concluded disclosure controls were effective as of September 30, 2018.

Investor verification priorities

  • Confirm cash runway and financing needs against subsequent cash burn, trial plans and available financing capacity.
  • Track Ovaprene trial enrollment, safety and efficacy findings, expected 2019 data timing, and the FDA’s PMA/IDE requirements.
  • Verify the timing, design and FDA alignment of the Sildenafil Cream Phase 2b program.
  • Assess the full potential cash, equity, milestone and royalty obligations in licensing and acquisition agreements.
  • Review dilution exposure from outstanding options and 3.75 million warrants, including the February 2018 warrants’ $3.00 exercise price and anti-dilution provisions.
  • Distinguish recurring development costs from the non-cash $5.19 million goodwill impairment and one-time acquisition-related costs when assessing operating trends.
Disclaimer:
This AI-generated summary by MetaQuotes is based on SEC filings and may contain errors. Verify important details against the original SEC filings.